Tardive Dyskinesia Drugs Market Consumption Analysis, Emerging Trends and Will Generate New Growth Opportunities Status 2027

“The Tardive Dyskinesia Drugs Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/218

Tardive dyskinesia is a rare involuntary, often mute, motor neural disease caused by the excessive use of dopamine antagonist drugs that are usually prescribed to treat some psychiatric or gastrointestinal disorders. Long term use of such drugs can produce severe biochemical changes in the brain’s reward system, the part of the brain which is involved in coordinating behavior with the actions of the body. The main causes that some of those who take such drugs might acquire tardive dyskinesia is unknown, but the main reasons that others don’t is still unknown.

Market Dynamics

High prevalence of neurological diseases is expected to propel growth of the tardive dyskinesia drugs market. For instance, according to the World Health Organization (WHO), the percentage of total disability-adjusted life years (DALYs) of epilepsy is expected to account for 0.5% while of cerebrovascular diseases for 3.6%. Moreover, percentage of total DALYs of cerebrovascular disease is projected to reach 3.9%, while that of epilepsy is expected to remain more or less constant by 2030. Moreover, high prevalence of tardive dyskinesia is also expected to aid in growth of the market. The average prevalence of tardive dyskinesia is estimated to be at least 20% of all patients who were treated with first-generation neuroleptics.

Increasing geriatric population is expected to offer lucrative growth opportunities for players in the tardive dyskinesia drugs market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Moreover, increasing sales of tardive dyskinesia drugs is also expected to aid in growth of the market. For instance, in January 2021, Neurocrine Biosciences, Inc. reported that full-year 2020 total INGREZZA (INGREZZA is a selective vesicular monoamine transporter 2 inhibitor indicated for the treatment of adults with tardive dyskinesia) prescriptions grew 32% to approximately 175,700 versus 2019 total prescriptions of approximately 132,700.

Major players operating in the tardive dyskinesia drugs market are focused on adopting various strategies to enhance their market share. For instance, in September 2020, Neurocrine Biosciences, Inc. announced to present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia and Parkinson’s disease at the virtual scientific meetings, 2020 Psych Congress and the MDS Virtual Congress 2020.

Top Key Players Include In Tardive Dyskinesia Drugs Market: Valeant Pharmaceuticals, Neurocrine Biosciences, and Teva Pharmaceutical Industries.

The Tardive Dyskinesia Drugs Market is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Tardive Dyskinesia Drugs Research Findings and Conclusion, Appendix, methodology and data source

Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/218

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]

Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog

“The Tardive Dyskinesia Drugs Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/218

Tardive dyskinesia is a rare involuntary, often mute, motor neural disease caused by the excessive use of dopamine antagonist drugs that are usually prescribed to treat some psychiatric or gastrointestinal disorders. Long term use of such drugs can produce severe biochemical changes in the brain’s reward system, the part of the brain which is involved in coordinating behavior with the actions of the body. The main causes that some of those who take such drugs might acquire tardive dyskinesia is unknown, but the main reasons that others don’t is still unknown.

Market Dynamics

High prevalence of neurological diseases is expected to propel growth of the tardive dyskinesia drugs market. For instance, according to the World Health Organization (WHO), the percentage of total disability-adjusted life years (DALYs) of epilepsy is expected to account for 0.5% while of cerebrovascular diseases for 3.6%. Moreover, percentage of total DALYs of cerebrovascular disease is projected to reach 3.9%, while that of epilepsy is expected to remain more or less constant by 2030. Moreover, high prevalence of tardive dyskinesia is also expected to aid in growth of the market. The average prevalence of tardive dyskinesia is estimated to be at least 20% of all patients who were treated with first-generation neuroleptics.

Increasing geriatric population is expected to offer lucrative growth opportunities for players in the tardive dyskinesia drugs market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Moreover, increasing sales of tardive dyskinesia drugs is also expected to aid in growth of the market. For instance, in January 2021, Neurocrine Biosciences, Inc. reported that full-year 2020 total INGREZZA (INGREZZA is a selective vesicular monoamine transporter 2 inhibitor indicated for the treatment of adults with tardive dyskinesia) prescriptions grew 32% to approximately 175,700 versus 2019 total prescriptions of approximately 132,700.

Major players operating in the tardive dyskinesia drugs market are focused on adopting various strategies to enhance their market share. For instance, in September 2020, Neurocrine Biosciences, Inc. announced to present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia and Parkinson’s disease at the virtual scientific meetings, 2020 Psych Congress and the MDS Virtual Congress 2020.

Top Key Players Include In Tardive Dyskinesia Drugs Market: Valeant Pharmaceuticals, Neurocrine Biosciences, and Teva Pharmaceutical Industries.

The Tardive Dyskinesia Drugs Market is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Tardive Dyskinesia Drugs Research Findings and Conclusion, Appendix, methodology and data source

Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/218

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]

Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog